Many pharmaceutical companies have been trying to conduct bridging studies since ICH E5 guideline adoption in Feb. 1998 and Japanese notification ﾒEthnic factors in the acceptability of foreign clinical dataﾓ in Aug. 1998.

The contents of this guideline are summarized and some examples which were approved by using foreign clinical data based on bridging concept are reviewed.